Trials / Completed
CompletedNCT05663957
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
An Observational Study to Assess the Real-World Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations Receiving Care in VA Health System in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,814 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the Department of Veterans Affairs (VA) Health System.
Detailed description
This a Phase IV observational, secondary data study to assess the effectiveness of Evusheld in preventing COVID-19 infection and severe outcomes using the electronic medical records from the nationwide integrated health system. The study is designed as an AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the VA Health System.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evusheld | EVUSHELD users |
Timeline
- Start date
- 2023-01-04
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
- First posted
- 2022-12-23
- Last updated
- 2024-09-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05663957. Inclusion in this directory is not an endorsement.